This signature, in addition to a smoking signature, CDKN2A/B loss, patient smoking status, and a tumor latency of <10 years represent a key set of molecular and clinical variables that characterize a tumor with poor prognosis following RT. This evidence concerns the gene CDKN2A and neoplasm.